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Coronavirus disease 2019 (COVID-19) is a global health crisis. There is currently a great need for effective and safe therapies directed at 
the disease, but no drugs are presently registered for use in COVID-19. Several directed therapies have been proposed, and most are still 
in clinical trials. Currently available published, peer-reviewed results mostly involve small sample sizes with study limitations restricting 
the interpretation of the findings. Many trials currently published also do not have a control group, limiting the interpretation of the effect 
of the intervention. Investigational directed therapies as well as investigational supportive therapies against COVID-19 are reviewed here. 
Chloroquine and hydroxychloroquine show promise as directed therapies, but current trial results are conflicting. Lopinavir/ritonavir 
also shows potential, but was started late in the disease course in most trials. No randomised controlled evidence is currently available for 
remdesivir and favipiravir. Corticosteroid use is not recommended for directed therapy against COVID-19, and the role of tocilizumab is 
currently unclear, based on limited evidence. Early initiation of investigational directed therapies may provide benefit in selected patients. 
The results from larger randomised controlled trials will clarify the place of these therapies in COVID-19 treatment.
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The novel coronavirus responsible for the coronavirus disease 2019 
(COVID-19) pandemic, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), was first identified in Wuhan, China in December 
2019.[1] The virus spread from China to many other countries in the 
world in a matter of weeks, leading the World Health Organization 
(WHO) to declare COVID-19 a pandemic in March 2020.[2] The clinical 
presentation is that of mild to moderate disease in 80% of patients,[3] 
but as of 17 April 2020, more than 130 000 people had died from 
COVID-19 worldwide, with 2 million infected.[4] Several risk factors for 
severe disease and death have been identified, including older age (≥65 
years old) and certain comorbid conditions including diabetes, chronic 
cardiac, renal, and liver disease, obesity and immunocompromise.[5] 
There is currently a great need for effective and safe therapies directed 
at COVID-19, but there are currently no registered drugs available 
for the treatment of COVID-19.[6] The generation and dissemination 
of publications on experimental targeted COVID-19 therapies is 
occurring at an unprecedentedly rapid pace. The international scientific 
community and clinicians must, however, guard against the acceptance, 
propagation and implementation of anecdotal evidence, as well as 
clinical trial results that are released prematurely. Results from non-
peer-reviewed, pre-print or uncontrolled trials must be interpreted via 
acknowledgment of their weaknesses and limitations. Findings from 
such trials, if used to guide clinical practice, may cause harm if the 
methodology, results and patient population are not properly appraised.
The management of milder cases is predominantly directed at 
symptomatic treatment, and the approach for moderate to severe 
presentations is mainly based on supplemental oxygen and supportive 
management.[7-9] Concomitant antibiotics and antivirals may also be 
used as empirical or definitive therapy for other pathogens.[9] The 
global clinical need for effective therapy has led to the investigational 
repurposing of registered drugs, as well as the early-phase testing of 
new antiviral drugs. Many of these drugs have already been investigated 
for SARS-CoV-1, Middle East respiratory syndrome (MERS) or Ebola 
virus, with inconsistent efficacy results.[10,11] There are currently no 
clear data from randomised controlled clinical trials on the effect of 
these drugs on COVID-19 outcomes, but several hundred clinical 
trials are presently registered to investigate their efficacy and safety in 
humans.[12,13] Below we briefly and narratively summarise the current 
evidence published in peer-reviewed scientific journals for the listed 
investigational therapies.
Investigational directed therapies for 
COVID-19
Chloroquine and hydroxychloroquine
Chloroquine (CQ) has been the backbone of malaria treatment and 
prevention for many decades. It is also used as an immunomodulator 
for rheumatological conditions such as systemic lupus erythematosus 
and rheumatoid arthritis (RA).[14] CQ has good in vitro activity against 
SARS-CoV-2.[15] The postulated mechanisms of action in COVID-19 
infection are threefold:[16] increasing endosomal pH that inhibits the 
SARS-CoV-2 spike protein cleavage required for viral/endosomal 
fusion after entry; interference with the glycosylation of cellular 
receptors (possibly through modification of angiotensin-converting 
enzyme 2 (ACE2), purported to be involved with viral entry);[11,17] 
and immunomodulation. Multiple trials across the globe are currently 
underway to assess the efficacy of CQ for the treatment and prevention 
of COVID-19, but no published, peer-reviewed results are available at 
the time of writing.[12,13,16,18]
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Similarly to CQ, hydroxychloroquine (HCQ) has in vitro activity 
against SARS-CoV-2.[15] HCQ was found to be more potent than CQ 
at inhibiting SARS-CoV-2 in vitro,[19] and is expected to have a similar 
mechanism of antiviral action to CQ.[20] HCQ is generally regarded as 
having fewer long-term adverse effects than CQ at equivalent doses, 
most notably retinopathy.[20,21] The mechanisms underlying this 
difference are currently unknown, but may be related to differences 
in drug accumulation, or the reduced propensity of HCQ to bind 
to eye tissues, compared with CQ.[22] Cardiotoxicity, especially QT-
prolongation, is, however, a significant risk with both drugs, even 
early in the treatment course.[23] The mechanism of drug-induced QT 
prolongation is through inhibition of the HERG/Kv11.1 potassium 
channels in the heart.[23] Inhibiting these channels increases the cardiac 
action potential duration, prolonging the QT interval and increasing 
the risk for torsades de pointes.[24] The risk of QT-prolongation is 
further compounded in patients with underlying cardiac disease or 
cardiac risk factors, and with the administration of concomitant QT-
prolonging medications or enzyme inhibitors.[23,25] The pervasive use 
of certain tuberculosis drugs and HIV antiretroviral therapy in the 
southern African setting may further increase the QT-prolongation 
risk.[26] Several risk-stratifying tools are currently available for drugs 
with QT-prolonging potential. A newly launched platform, MedSafety 
Scan (https://medsafetyscan.org), has been made available online to 
guide clinicians on risk and clinical decision-making when they input 
patients’ QT-prolonging drugs and selected clinical factors. The risk of 
CQ and HCQ to cause QT prolongation is based on the well-known 
CredibleMeds (https://crediblemeds.org) database.
The currently available evidence on the use of HCQ in COVID-19 
comes from four published, peer-reviewed trials. Gautret et al.[27] 
suggested in a small, open-label, non-randomised trial that HCQ 
together with azithromycin (AZM) may be more effective in reducing 
viral shedding by day 6 post-treatment than HCQ alone, or controls. 
Of note is that the effect of AZM was not prospectively assessed with 
HCQ, as the AZM was only given to some patients as part of standard 
of care if the clinical presentation warranted it. The association of 
AZM and HCQ in the reduction of viral shedding was therefore made 
after the fact. Some limitations of this trial were the small sample size 
and lack of power (only six participants received HCQ and AZM), 
no reporting of clinical outcomes and exclusion of participants 
who died or were sent to the intensive care unit (ICU). The authors 
commented that the addition of AZM to HCQ may increase the risk 
of QT-prolongation, but that the potential antiviral activity of AZM 
and the synergistic effect with HCQ may justify the combination on a 
case-by-case basis. Gautret et al.[28] published a follow-on uncontrolled 
study with a larger sample size (n=80). Primary endpoints were the 
need for oxygen therapy or transfer to the ICU after at least 3 days 
of treatment, contagiousness as assessed by viral real-time reverse-
transcriptase polymerase chain reaction (RT-PCR) and culture, and 
length of stay in the study ward. Dosages used were oral HCQ sulphate 
200 mg three times a day for 10 days, combined with AZM 500 mg 
on day 1, followed by 250 mg per day for the next 4 days. HCQ with 
AZM was not started in patients in whom the cardiac risk was deemed 
too high. The primary endpoint was reached in 18.8% of participants, 
who required oxygen therapy or transfer to the ICU. Viral RT-PCR 
was negative in 83% at day 7, and 100% at day 12 post treatment. Viral 
cultures were negative in 97.5% of participants at day 5. Sixty-five 
of the 80 participants were discharged from the study ward during 
the trial period, with a mean time from initiation to discharge of 4.1 
days. The findings of this trial are difficult to interpret, as participants 
were not randomised, nor was there a control group. Study limitations 
further include that most participants (92%) were considered low risk 
for clinical deterioration at enrolment, and this low risk continued 
until discharge in most (93.8%). Four asymptomatic patients were also 
included in the trial, and more than three-quarters of participants 
were younger than the high-risk age group of ≥65 years old.[5] The 
majority of participants had a low risk for clinical deterioration, and 
the observation of negative RT-PCR tests in 83% of participants by 
day 7 after treatment initiation – therefore at a median of day 12 after 
symptom onset – could well be in keeping with the natural course of 
the disease.[3,31]
In response to the first publication by Gautret et al.,[27] Molina et 
al.[30] replicated the design and dosages of HCQ and AZM in their 
own trial to assess whether similar findings were observed. They 
prospectively enrolled 11 consecutively hospitalised patients with 
severe COVID-19. Paired RT-PCR results were available in 10 
participants, with 8 still testing positive at days 5 - 6 after treatment 
initiation. The authors conclude that their findings stand in contrast 
to those reported by Gautret et al.,[27] and cast doubt on the strong 
antiviral efficacy of the combination of HCQ and AZM.[30] Limitations 
of this trial include a small sample size, no control group and limited 
information on clinical outcomes.
A Chinese study evaluated 30 participants randomised to receive 
HCQ sulphate 400 mg once a day for 5 days with standard of care 
(n=15), or standard of care alone (n=15).[31] The study endpoints 
were virological clearance by day 7, or death. The authors found no 
difference between the two groups for virological clearance (86.7% 
in the interventional group v. 93.3% in the standard of care group; 
p>0.05). None of the participants died during the 2-week follow-up 
period.[31] 
In summary, trials assessing HCQ and CQ in COVID-19 to date have 
mostly been uncontrolled, and have shown conflicting results. Owing 
to methodological limitations, the results are difficult to interpret, and 
there are currently insufficient clinical data to recommend either for 
or against the use of CQ and HCQ in COVID-19 outside of the clinical 
trial setting.[32]
Lopinavir/ritonavir (with or without interferon)
Lopinavir and ritonavir are both protease inhibitors. Ritonavir is used in 
combination with lopinavir to increase lopinavir plasma concentrations 
by inhibiting the enzymatic metabolism of lopinavir.[33] The rationale 
for the use of lopinavir/ritonavir (LPV/r) in COVID-19 stems 
from its in vitro activity against SARS-CoV-1,[34] as well as from 
a retrospective, multicentre cohort study evaluating LPV/r as 
early treatment in SARS-CoV-1, which demonstrated decreased 
mortality and intubation rates.[35] Numerous case reports and 
case series have shown successful management of COVID-19 
patients with LPV/r.[36-41] Nevertheless, some patients on LPV/r still 
progressed to severe disease, although in most such cases LPV/r was 
only started late in the disease course. It is therefore unclear whether 
the observed effect was due to the intervention or to the natural 
course of the disease. In a retrospective cohort study of 33 patients 
receiving LPV/r 400/100 mg twice a day, all patients tested negative 
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with RT-PCR by day 14.[42] Wan et al.[43] reported the clinical features 
and treatment of COVID-19 in a case series of 135 patients in China. 
They reported that LPV/r and interferon administered to all patients 
in early-stage disease resulted in the discharge of 15 patients and the 
death of 1 patient at the end of the 16-day study period. A total of 
119 patients were still hospitalised at the end of the study period. The 
doses of LPV/r, and the doses and type of interferon used, were not 
stated. In vitro studies of interferon have demonstrated inhibition 
of SARS-CoV-1 infection, but only in combination with other 
antiviral agents.[44] Several clinical trials are currently evaluating 
various treatment combinations with interferon.[12,13] The most 
robust evidence for LPV/r in SARS-CoV-2 currently comes from a 
Chinese randomised controlled trial that evaluated its efficacy and 
safety.[45] The primary outcome was the time to clinical improvement. 
One hundred and ninety-nine participants were individually 
randomised to LPV/r (n=99) at a dose of 400/100 mg twice a day 
with standard of care, or standard of care alone (n=100), for 14 days. 
The results showed that the time to clinical improvement between the 
two groups was similar, with a median of 16 days for both (hazard 
ratio for clinical improvement 1.31; 95% confidence interval 0.95 - 
1.80; p=0.09).[47] Recorded adverse events included nausea, vomiting 
and diarrhoea, all of which were more common in the LPV/r group 
than the standard of care group. Four gastrointestinal-related serious 
adverse events reported in the LPV/r group were deemed to be related 
to LPV/r. Limitations included the open-label design of the trial, the 
initiation of investigational treatment late in the disease course (a 
median of 13 days after symptom onset) and the fact that both groups 
were heterogeneous and received various additional treatments. In 
summary, LPV/r does not currently have robust evidence for use in 
COVID-19, but the mostly conflicting results from currently available 
data should be interpreted in light of the study designs and timing 
of LPV/r in the disease course. At the time of writing, LPV/r is not 
recommended for use, other than as part of clinical trials.[32]
Remdesivir
Remdesivir is in early-phase drug development, and currently being 
investigated for COVID-19 therapy. Remdesivir was originally 
developed for use against the Ebola virus in 2015,[46] and has shown 
promising in vitro activity against SARS-CoV-2.[15] It acts as a nucleotide 
analogue, causing premature termination of viral RNA replication by 
inhibiting RNA polymerase.[47] Although remdesivir is not yet registered 
by any medicines regulatory authority for human use, its safety profile 
was established in a randomised controlled trial during the Ebola virus 
outbreak in the Democratic Republic of Congo.[46] Several clinical trials 
are currently registered for the investigation of remdesivir,[12,13] but 
no robust results are yet available. Remdesivir has, however, been 
approved for compassionate use in several countries, and a recent 
preliminary report described the outcomes in a cohort of patients 
hospitalised for severe COVID-19 who were treated with remdesivir 
on a compassionate-use basis.[48] The authors described the outcomes 
of 53 participants, and reported that after a median follow-up of 18 
days, 68% of the participants had an improvement in terms of their 
required oxygen support. Of 34 participants who initially required 
mechanical ventilation, 9 remained ventilated, 3 were switched 
to non-invasive ventilation, 8 were weaned off oxygen and 8 were 
discharged. Six participants who were initially ventilated died, and 
the overall mortality rate was 13%. A significant limitation of this 
report is the protracted duration of symptoms before remdesivir was 
started (median (interquartile range) 12 (9 - 15) days). Additionally, 
the absence of a control group limits the interpretation of the effect 
of remdesivir. Concomitant therapies and viral loads were also not 
reported. In summary, there are currently insufficient clinical data 
available to recommend either for or against the use of remdesivir in 
COVID-19, outside of clinical trials.[32]
Favipiravir
Favipiravir is an antiviral drug approved for the management of 
influenza in Japan.[49] It is currently being evaluated in clinical trials 
for the management of COVID-19.[12] It is a nucleic acid analogue 
that is incorporated into viral RNA to affect viral replication and 
possibly RNA polymerase.[50] At the time of writing, there were no 
published peer-reviewed trials or case studies evaluating favipiravir 
in COVID-19, and its use is not currently recommended outside of 
clinical trials.
Investigational supportive therapies for 
COVID-19
Tocilizumab
Tocilizumab is a monoclonal antibody used for the treatment of 
several rheumatic conditions, including RA and juvenile idiopathic 
arthritis.[11,51] The US Food and Drug Administration additionally 
approved tocilizumab in 2017 for the treatment of cytokine release 
syndrome (CRS, also known as cytokine storm) caused by chimeric 
antigen receptor T-cell therapy, an immunomodulatory approach used 
in oncology.[52] Tocilizumab is a recombinant humanised monoclonal 
antibody against the interleukin 6 (IL-6) receptor. It binds both 
soluble and membrane-bound IL-6 receptors, inhibiting IL-6 signal 
transduction.[52] Patients with severe disease during the previous 
outbreaks of SARS-CoV-1[53] and MERS[54] were found to have elevated 
concentrations of IL-6. Patients who died due to COVID-19 were also 
found to have increased markers for CRS, including raised IL-6.[40] 
It is therefore postulated that the current severe organ dysfunction 
observed in COVID-19 may be due to CRS, and that IL-6 inhibitors 
such as tocilizumab may attenuate this immune reaction.[11,55,56]
A retrospective observational study from a single centre in China 
reported on the use of tocilizumab in 15 COVID-19 patients.[57] The 
study population was older patients, aged between 62 and 80 years. 
Most patients were severely or critically ill, and over half received 
a course of methylprednisolone. One-third of the patients (5/15) 
received two or more doses of tocilizumab. The authors report 
increasing IL-6 concentrations after tocilizumab initiation followed by 
a decrease in most patients who improved clinically. Five patients died 
or had disease aggravation, with IL-6 concentrations increasing in all 
five. Limitations include the small sample size and the non-reporting 
of the duration of symptoms before treatment was started, or whether 
other investigational therapy was given as well. Several case reports 
and a case series have also been published describing the effect of 
tocilizumab in patients with various underlying conditions.[58-61] All 
showed improvement, but these reports included patients who were 
started on tocilizumab after inadequate response to standard of care. 
It is unclear what the effect of tocilizumab was in these cases, as it was 
started late in the disease course and the clinical improvement may 
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have been in keeping with the natural course of the disease. Numerous 
randomised trials are currently underway to evaluate tocilizumab in 
COVID-19.[12,13]
Corticosteroids
The WHO advises against the use of corticosteroids in the 
management of targeted COVID-19 owing to potential harmful 
effects.[9] This is largely based on previous experiences of 
corticosteroid therapy in influenza and MERS-CoV. A systematic 
review of treatment options in SARS-CoV-1 infection included 
corticosteroids’ effects on mortality, in vitro inhibition of SARS viral 
replication and acute respiratory distress syndrome.[62] The study 
concluded that the evidence for the effects of corticosteroids in the 
management of SARS-CoV-1 was either inconclusive or showed 
that they conferred possible harm.[62] However, the studies included 
were of poor-quality evidence. A Cochrane review[63] of observational 
studies of corticosteroids as adjunctive therapy in the treatment of 
influenza found an increased risk of mortality. The included studies 
demonstrated significant heterogeneity across the group as a whole, 
and the quality of evidence was graded as low.[63] 
A subsequent observational cohort study investigating influenza 
adjusted for baseline and time-dependent characteristics, and 
matching treatment groups according to propensity scores, found 
no association between the use of corticosteroids and mortality in 
influenza.[64] In MERS-CoV, there was an association between delayed 
viral clearance and the use of corticosteroids, but no association 
with 90-day mortality.[64] The major limitation of this study was the 
retrospective observational design, with possible confounding by 
indication. Nevertheless, owing to the possibility of potential harm by 
corticosteroids in viral infections, the WHO recommends against the 
routine use of corticosteroids in COVID-19 patients, unless used with 
caution for other indications where there are supportive data, such 
as sepsis and acute exacerbations of asthma and chronic obstructive 
pulmonary disease, or as part of clinical trials.[9] Patients infected with 
COVID-19 subsequently require a risk-benefit assessment prior to the 
use of corticosteroids. At the time of writing there were no published, 
peer-reviewed studies on the use of corticosteroids in COVID-19, but 
several clinical trials are underway.[12,13]
Timing of investigational directed 
therapies for COVID-19
Several of the above trials have shown that results from investigational 
therapies that were started late in the disease course are difficult to 
interpret, as the outcomes observed may have been masked by 
irreversible systemic injury (no difference compared with standard 
of care), or natural course of the disease (improvement regardless of 
the therapy). Clinical trials will subsequently require large sample 
sizes to determine if the investigational directed therapy is in fact 
effective for smaller treatment effects later in the disease course. In 
addition, investigational supportive therapies such as tocilizumab may 
be more effective when given later in the disease course with more 
severe immunopathology, acting to decrease organ damage in the 
presence of CRS. Conversely, some therapies may be more beneficial 
when given early. Oseltamivir, an antiviral drug used for influenza 
virus infection, has been shown to be more effective when given 48 - 
72 hours after symptom onset.[65] The rationale is that influenza viral 
replication peaks at 24 - 72 hours after symptom onset,[66] and viral 
replication inhibitors such as oseltamivir should be given no later 
than at the peak of viral replication. Drugs that purportedly inhibit 
SARS-CoV-2 replication (such as the investigational antivirals) or 
viral entry and replication (CQ and HCQ) may therefore be more 
effective when given earlier in the COVID-19 disease course. Patients 
who may benefit from earlier treatment initiation include those with 
confirmed COVID-19 who do not require hospitalisation, but have 
significant risk factors.
Conclusion
There is a pressing need globally to find effective treatment options 
for COVID-19. Current strategies to curtail the pandemic are aimed 
at infection prevention and control, and supportive management of 
those with infections of varying severity. The hope of effective and 
safe large-scale preventive strategies such as vaccines seems to still 
be several months away. In the interim, numerous clinical trials are 
ongoing to investigate various repurposed and experimental drugs, 
but no published, peer-reviewed trial to date has provided clear 
evidence of significant benefit with permissible safety for any drug 
for COVID-19. In selected patients, early initiation of investigational 
directed therapy may be of benefit due to reduced viral replication 
and/or entry. Amid the turmoil of the current pandemic, investigators 
and sponsors should as far as possible conduct COVID-19 trials in a 
way that allows for clear interpretation of the results, and the scientific 
community should continue to uphold the rigorous principles of 
evidence-based medicine and proper conduct and reporting of 
clinical trials.
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